10 research outputs found
Antitumor Activity of 1,18-Octadecanedioic Acid-Paclitaxel Complexed with Human Serum Albumin
Therapeutic Enzyme-Responsive Nanoparticles for Targeted Delivery and Accumulation in Tumors.
Disrupting the Interplay between Programmed Cell Death Protein 1 and Programmed Death Ligand 1 with Spherical Nucleic Acids in Treating Cancer
Disrupting the interplay between programmed cell death
protein
1 (PD-1) and programmed death ligand 1 (PD-L1) is a powerful immunotherapeutic
approach to cancer treatment. Herein, spherical nucleic acid (SNA)
liposomal nanoparticle conjugates that incorporate a newly designed
antisense DNA sequence specifically against PD-L1 (immune checkpoint
inhibitor SNAs, or IC-SNAs) are explored as a strategy for blocking
PD-1/PD-L1 signaling within the tumor microenvironment (TME). Concentration-dependent
PD-L1 silencing with IC-SNAs is observed in MC38 colon cancer cells,
where IC-SNAs decrease both surface PD-L1 (sPD-L1) and total PD-L1
expression. Furthermore, peritumoral administration of IC-SNAs in
a syngeneic mouse model of MC38 colon cancer leads to reduced sPD-L1
expression in multiple cell populations within the TME, including
tumor cells, dendritic cells, and myeloid derived suppressor cells.
The treatment effectively increases CD8+ T cells accumulation
and functionality in the TME, which ultimately inhibits tumor growth
and extends animal survival. Taken together, these data show that
IC-SNA nanoconstructs are capable of disrupting the PD-1/PD-L1 interplay
via gene regulation, thereby providing a promising avenue for cancer
immunotherapy
Tumor Retention of Enzyme-Responsive Pt(II) Drug-Loaded Nanoparticles Imaged by Nanoscale Secondary Ion Mass Spectrometry and Fluorescence Microscopy.
In nanomedicine, determining the spatial distribution of particles and drugs, together and apart, at high resolution within tissues, remains a major challenge because each must have a different label or detectable feature that can be observed with high sensitivity and resolution. We prepared nanoparticles capable of enzyme-directed assembly of particle therapeutics (EDAPT), containing an analogue of the Pt(II)-containing drug oxaliplatin, an 15N-labeled monomer in the hydrophobic block of the backbone of the polymer, the near-infrared dye Cy5.5, and a peptide that is a substrate for tumor metalloproteinases in the hydrophilic block. When these particles reach an environment rich in tumor associated proteases, the hydrophilic peptide substrate is cleaved, causing the particles to accumulate through a morphology transition, locking them in the tumor extracellular matrix. To evaluate the distribution of drug and EDAPT carrier in vivo, the localization of the isotopically labeled polymer backbone was compared to that of Pt by nanoscale secondary ion mass spectrometry (NanoSIMS). The correlation of NanoSIMS with super-resolution fluorescence microscopy revealed the release of the drug from the nanocarrier and colocalization with cellular DNA within tumor tissue. The results confirmed the dependence of particle accumulation and Pt(II) drug delivery on the presence of a Matrix Metalloproteinase (MMP) substrate and demonstrated antitumor activity. We conclude that these techniques are powerful for the elucidation of the localization of cargo and carrier, and enable a high-resolution assessment of their performance following in vivo delivery
Recommended from our members
Tumor Retention of Enzyme-Responsive Pt(II) Drug-Loaded Nanoparticles Imaged by Nanoscale Secondary Ion Mass Spectrometry and Fluorescence Microscopy.
In nanomedicine, determining the spatial distribution of particles and drugs, together and apart, at high resolution within tissues, remains a major challenge because each must have a different label or detectable feature that can be observed with high sensitivity and resolution. We prepared nanoparticles capable of enzyme-directed assembly of particle therapeutics (EDAPT), containing an analogue of the Pt(II)-containing drug oxaliplatin, an 15N-labeled monomer in the hydrophobic block of the backbone of the polymer, the near-infrared dye Cy5.5, and a peptide that is a substrate for tumor metalloproteinases in the hydrophilic block. When these particles reach an environment rich in tumor associated proteases, the hydrophilic peptide substrate is cleaved, causing the particles to accumulate through a morphology transition, locking them in the tumor extracellular matrix. To evaluate the distribution of drug and EDAPT carrier in vivo, the localization of the isotopically labeled polymer backbone was compared to that of Pt by nanoscale secondary ion mass spectrometry (NanoSIMS). The correlation of NanoSIMS with super-resolution fluorescence microscopy revealed the release of the drug from the nanocarrier and colocalization with cellular DNA within tumor tissue. The results confirmed the dependence of particle accumulation and Pt(II) drug delivery on the presence of a Matrix Metalloproteinase (MMP) substrate and demonstrated antitumor activity. We conclude that these techniques are powerful for the elucidation of the localization of cargo and carrier, and enable a high-resolution assessment of their performance following in vivo delivery
Dual-responsive nanoparticles release cargo upon exposure to matrix metalloproteinase and reactive oxygen species
Recommended from our members
Antitumor Activity of 1,18-Octadecanedioic Acid-Paclitaxel Complexed with Human Serum Albumin.
We describe the design, synthesis, and antitumor activity of an 18 carbon α,ω-dicarboxylic acid monoconjugated via an ester linkage to paclitaxel (PTX). This 1,18-octadecanedioic acid-PTX (ODDA-PTX) prodrug readily forms a noncovalent complex with human serum albumin (HSA). Preservation of the terminal carboxylic acid moiety on ODDA-PTX enables binding to HSA in the same manner as native long-chain fatty acids (LCFAs), within hydrophobic pockets, maintaining favorable electrostatic contacts between the ω-carboxylate of ODDA-PTX and positively charged amino acid residues of the protein. This carrier strategy for small molecule drugs is based on naturally evolved interactions between LCFAs and HSA, demonstrated here for PTX. ODDA-PTX shows differentiated pharmacokinetics, higher maximum tolerated doses and increased efficacy in vivo in multiple subcutaneous murine xenograft models of human cancer, as compared to two FDA-approved clinical formulations, Cremophor EL-formulated paclitaxel (crPTX) and Abraxane (nanoparticle albumin-bound (nab)-paclitaxel)
Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer
The future of scientific leadership is interdisciplinary: The 2019 CAS Future Leaders share their vision
For the last decade, the CAS Future Leaders program has gathered early-career scientists from across the globe based on their outstanding accomplishments in the field of chemistry to provide support to participants in cultivating their own voices and futures in scientific leadership. The goal of the program has been to empower early-career scientists like us to begin to shape our own future leadership roles, from learning to convey effective speech by developing our own research stories to growing to be better mentors for the next generation of future leaders. In 2019, to honor the 10th anniversary of the program, the CAS Future Leaders program encompassed essential leadership skills divided into five topics, namely, storytelling, insights, strategies, perspectives, and impact, some of which were new to the program this year. However, what was not new to the program was an emphasis on the potential global impact that this program could make. To do this, the program brought together in this cohort 29 post-docs and graduate students, from 16 countries. A staple of this program is not only the breadth of countries that are represented but also the many facets of chemistry that are represented as demonstrated later in the article. One reason for this is that a leader in the sciences will need to be open to innovations across discipline and geographical boundaries, something that we explored a lot during our time together